LLY

928.56

+2.46%↑

JNJ

186.29

-0.27%↓

UNH

327.86

-0.81%↓

NVS

125.19

+0.06%↑

ABT

124.68

-0.87%↓

LLY

928.56

+2.46%↑

JNJ

186.29

-0.27%↓

UNH

327.86

-0.81%↓

NVS

125.19

+0.06%↑

ABT

124.68

-0.87%↓

LLY

928.56

+2.46%↑

JNJ

186.29

-0.27%↓

UNH

327.86

-0.81%↓

NVS

125.19

+0.06%↑

ABT

124.68

-0.87%↓

LLY

928.56

+2.46%↑

JNJ

186.29

-0.27%↓

UNH

327.86

-0.81%↓

NVS

125.19

+0.06%↑

ABT

124.68

-0.87%↓

LLY

928.56

+2.46%↑

JNJ

186.29

-0.27%↓

UNH

327.86

-0.81%↓

NVS

125.19

+0.06%↑

ABT

124.68

-0.87%↓

Search

Revvity Inc

Closed

SectorHealthcare

92.63 1

Overview

Share price change

24h

Current

Min

89.87

Max

93.05

Key metrics

By Trading Economics

Income

-8.6M

47M

Sales

-21M

699M

P/E

Sector Avg

47.923

77.256

EPS

1.18

Dividend yield

0.3

Profit margin

6.675

Employees

11,000

EBITDA

-14M

181M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+21.17% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

0.30%

2.33%

Next Dividend date

7 lis 2025

Next Ex Dividend date

16 sty 2026

Market Stats

By TradingEconomics

Market Cap

-486M

11B

Previous open

91.63

Previous close

92.63

News Sentiment

By Acuity

28%

72%

64 / 373 Ranking in Healthcare

Revvity Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

5 lis 2025, 23:51 UTC

Earnings

CoreCivic Cuts Fiscal Year Guidance Amid Efforts to Launch New Detention Facilities

5 lis 2025, 23:10 UTC

Earnings

DBS Third Quarter Net Dips 2.0%

5 lis 2025, 22:55 UTC

Earnings

Arm Holdings 2Q Profit Climbs on Record Demand

5 lis 2025, 22:23 UTC

Earnings

NAB's Annual Profit Falls 2.9% Amid Higher Costs, Credit Impairments -- Update

5 lis 2025, 23:52 UTC

Earnings

United Overseas Bank 3Q Net Interest Income S$2.265B Vs. $2.46B >U11.SG

5 lis 2025, 23:49 UTC

Earnings

United Overseas Bank 3Q Total Income S$3.40B Vs. S$3.83B >U11.SG

5 lis 2025, 23:49 UTC

Earnings

United Overseas Bank 3Q Net S$443M Vs. Net S$1.61B >U11.SG

5 lis 2025, 23:45 UTC

Market Talk

Nikkei May Rise on Weaker Yen, U.S. Tech Rebound -- Market Talk

5 lis 2025, 23:42 UTC

Market Talk

Gold Edges Lower Amid Reduced Odds of Fed Rate-Cut -- Market Talk

5 lis 2025, 23:12 UTC

Earnings

Nutrien 3Q Adj EPS 97c >NTR.T

5 lis 2025, 23:11 UTC

Earnings

Nutrien: Initiating Review of Strategic Alternatives for Phosphate Business >NTR.T

5 lis 2025, 23:10 UTC

Earnings

Nutrien 3Q Sales $6.01B >NTR.T

5 lis 2025, 23:10 UTC

Market Talk
Earnings

AppLovin Says Conversion Rate Is Biggest Growth Lever -- Market Talk

5 lis 2025, 23:10 UTC

Earnings

Nutrien 3Q EPS 96c >NTR.T

5 lis 2025, 23:04 UTC

Earnings

Qualcomm Stock Slides After Earnings Beat -- Barrons.com

5 lis 2025, 23:03 UTC

Market Talk

Macklem: Canada's Regulatory Overlap Turns Off Foreign Investors -- Market Talk

5 lis 2025, 22:55 UTC

Market Talk

Macklem Says Inflation and Productivity Are Intertwined -- Market Talk

5 lis 2025, 22:55 UTC

Earnings

AppLovin Reports Strong Earnings. The Stock Is Up. -- Barrons.com

5 lis 2025, 22:51 UTC

Earnings

DBS 3Q Total Income S$5.93B, Up 3% on Year >D05.SG

5 lis 2025, 22:50 UTC

Earnings

DBS 3Q Net S$2.95B, Down 2.0% on Year >D05.SG

5 lis 2025, 22:44 UTC

Acquisitions, Mergers, Takeovers

Pfizer Preps Improved Offer in Metsera Bidding War -- Update

5 lis 2025, 22:43 UTC

Market Talk
Earnings

NAB's Flat Dividend Disappoints Bears at Jarden -- Market Talk

5 lis 2025, 22:36 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

5 lis 2025, 22:36 UTC

Market Talk

Macklem Warns Structural Adjustment Means Slow Canadian Growth -- Market Talk

5 lis 2025, 22:20 UTC

Market Talk

Bank of Canada Says Budget Plan Identifies Economy's Biggest Weakness -- Market Talk

5 lis 2025, 22:12 UTC

Acquisitions, Mergers, Takeovers

Pfizer: Will Take Action to Preserve Rights Under Previously-Signed Agreement >PFE

5 lis 2025, 22:11 UTC

Acquisitions, Mergers, Takeovers

Pfizer: Confident in Merits of Claims, Belief Metsera Has Acted in Breach of Contractual Obligations >PFE

5 lis 2025, 22:11 UTC

Acquisitions, Mergers, Takeovers

Pfizer Responds to Delaware Chancery Court Ruling

5 lis 2025, 22:01 UTC

Earnings

Great-West Lifeco 3Q Net C$1.16B >GWO.T

5 lis 2025, 22:01 UTC

Earnings

Great-West Lifeco 3Q Adj EPS C$1.33 >GWO.T

Peer Comparison

Price change

Revvity Inc Forecast

Price Target

By TipRanks

21.17% upside

12 Months Forecast

Average 111.1 USD  21.17%

High 125 USD

Low 100 USD

Based on 11 Wall Street analysts offering 12 month price targets forRevvity Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

11 ratings

8

Buy

3

Hold

0

Sell

Sentiment

By Acuity

64 / 373 Ranking in Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Revvity Inc

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
help-icon Live chat